RxDoctor Payments Data

Kimberly Flowers

Gerontology · Portland, ORNPI 1366045924

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,960 of the $5,053 with a category attached, or 78.4%. 16 manufacturers reported payments, led by Medtronic at 39.0% of the total. Reporting peaked in 2024 at $2,214 and has fallen 59.4% since, to $898 in 2025. Among gerontology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,053in general payments, 2019–2025

Across 71 payments — averaging $71.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Novo Nordisk$793
  • AstraZeneca$354
  • Mannkind Corporation$318
  • Boehringer Ingelheim$242
  • BETA Bionics, Inc.$222
  • plus $1K from 10 others

What the payments were for

  • Travel & lodging$1,09222%
  • Food & beverage$3,96078%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,053 in reported general payments places this provider in the 95th percentile of 53 gerontology providers in Oregon.

See all gerontology providers in Oregon

Medicare billing

Part B allowed, 2024
$39,314
Medicare patients
232
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide314$436,338
JardianceEmpagliflozin278$357,682
MounjaroTirzepatide216$334,875
TrulicityDulaglutide219$329,108
Humulin R U-500 KwikpenInsulin Regular, Human30$81,221
FarxigaDapagliflozin Propanediol63$78,325
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog135$69,705
Humalog Kwikpen U-200Insulin Lispro24$64,092
Lantus SolostarInsulin Glargine,hum.Rec.Anlog298$56,197
Humalog Kwikpen U-100Insulin Lispro127$47,972
Tresiba Flextouch U-200Insulin Degludec21$45,836
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/735$42,938
RybelsusSemaglutide22$36,597
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$33,718
Novolog FlexpenInsulin Aspart97$29,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro, Baqsimi$117$699,756562 claims
Novo NordiskOzempic, Rybelsus, Novolog$793$487,913384 claims
Boehringer IngelheimJardiance$242$357,682278 claims
AstraZenecaFarxiga$354$78,32563 claims
Sanofi-aventis U.S. LLCLantus$91$22,890107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 gerontology providers in Oregon.

Other gerontology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →